(b) “Electroencephalogram combined Transcranial Magnetic Stimulation” or “eTMS” means treatment in which transcranial magnetic stimulation frequency pulses are tuned to the patient’s physiology and biometric data.
(c) “First responder” means a law enforcement officer, a part-time law enforcement officer, or an auxiliary law enforcement officer as defined in s. 943.10; a firefighter as defined in s. 633.102; a 911 public safety telecommunicator as defined in s. 401.465; or an emergency medical technician or paramedic as defined in s. 401.23 employed by state or local government. The term also includes a volunteer or retired law enforcement officer, firefighter, or emergency medical technician or paramedic engaged, or previously engaged, by the state or a local government.
(d) “Veteran” means:
2. A person who served in a reserve component as defined in 38 U.S.C. s. 101(27); or
3. A person who served in the National Guard of any state.
(b) Mental illness.
(c) Sleep disorders.
(d) Traumatic brain injuries.
(e) Sexual trauma.
(f) Posttraumatic stress disorder and accompanying comorbidities.
(g) Concussions.
(h) Other brain trauma.
(i) Quality of life issues affecting human performance, including issues related to or resulting from problems with cognition and problems maintaining attention, concentration, or focus.
(4) The pilot program shall include:
(b) The requirement that each individual who receives treatment under the program also must receive neurophysiological monitoring, monitoring for symptoms of substance use and other mental health disorders, and access to counseling and wellness programming. Each individual who receives treatment must also participate in the peer-to-peer support network established by the provider.
(c) The establishment of protocols which include the use of adopted stimulation frequency and intensity modulation based on EEGs done on days 0, 10, and 20 and motor threshold testing, as well as clinical symptoms, signs, and biometrics.
(d) The requirement that protocols and outcomes of any treatment provided by the clinical practice shall be collected and reported by the provider quarterly to the division, the President of the Senate, and the Speaker of the House of Representatives. Such report shall include the biodata metrics and all expenditures and accounting of the use of funds received from the department.
(e) The requirement that protocols and outcomes of any treatment provided by the clinical practice shall be collected and reported to the University of South Florida and may be provided by the provider to any relevant Food and Drug Administration studies or trials.
(6) This section expires July 1, 2026.
